Investigational Drug Information for PU-H71
✉ Email this page to a colleague
What is the development status for investigational drug PU-H71?
PU-H71 is an investigational drug.
There have been 5 clinical trials for PU-H71.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 24th 2018.
The most common disease conditions in clinical trials are Thrombocytosis, Neoplasms, and Thrombocythemia, Essential. The leading clinical trial sponsors are Samus Therapeutics, Inc., Memorial Sloan Kettering Cancer Center, and National Cancer Institute (NCI).
Summary for PU-H71
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 288 |
| WIPO Patent Applications | 120 |
| Japanese Patent Applications | 57 |
| Clinical Trial Progress | Phase 1 (2018-05-24) |
| Vendors | 58 |
Recent Clinical Trials for PU-H71
| Title | Sponsor | Phase |
|---|---|---|
| Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib | Samus Therapeutics, Inc. | Phase 1 |
| Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis | Samus Therapeutics, Inc. | Phase 1 |
| PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer | Samus Therapeutics, Inc. | Phase 1 |
Clinical Trial Summary for PU-H71
Top disease conditions for PU-H71
Top clinical trial sponsors for PU-H71
US Patents for PU-H71
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
